Apyx Medical Inc

Healthcare US APYX

1.465USD
0.04(2.45%)

Last update at 2025-05-19T18:52:00Z

Day Range

1.331.50
LowHigh

52 Week Range

1.217.97
LowHigh

Fundamentals

  • Previous Close 1.43
  • Market Cap54.74M
  • Volume34997
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-20.05900M
  • Revenue TTM50.45M
  • Revenue Per Share TTM1.46
  • Gross Profit TTM 29.13M
  • Diluted EPS TTM-0.65

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -22.91100M -14.82000M -19.40900M -19.91000M -13.27100M
Minority interest -0.09400M -0.02800M 0.14M 0.14M 0.14M
Net income -23.27800M -15.20000M -11.90600M -19.65000M 64.01M
Selling general administrative 48.15M 43.73M 33.67M 36.23M 21.18M
Selling and marketing expenses - - - - -
Gross profit 29.13M 33.60M 17.50M 19.13M 10.79M
Reconciled depreciation 0.89M 0.90M 0.89M 0.75M 0.67M
Ebit -23.56200M -14.44800M -20.08300M -20.91200M -13.73100M
Ebitda -22.89600M -14.81000M -19.36300M -19.90200M -13.06200M
Depreciation and amortization 0.67M -0.36200M 0.72M 1.01M 0.67M
Non operating income net other 0.65M -0.37200M 0.67M 1.03M 0.33M
Operating income -23.56200M -14.44800M -20.08300M -20.91200M -13.60000M
Other operating expenses 68.07M 62.97M 47.79M 49.07M 29.55M
Interest expense 0.01M 0.01000M 0.05M 0.00800M 0.51M
Tax provision 0.37M 0.38M -7.50300M -0.13000M -3.77700M
Interest income 0.16M 0.01M 0.24M 1.39M 0.62M
Net interest income 0.14M 0.00100M 0.20M 1.38M 0.51M
Extraordinary items - - - - 73.50M
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.37M 0.38M -7.50300M -0.26000M -3.77700M
Total revenue 44.51M 48.52M 27.71M 28.15M 16.69M
Total operating expenses 52.69M 48.05M 37.59M 40.04M 23.65M
Cost of revenue 15.38M 14.92M 10.21M 9.03M 5.89M
Total other income expense net 0.65M -0.37200M 0.67M 1.00M -0.92400M
Discontinued operations - - - - 73.50M
Net income from continuing ops -23.27800M -15.20000M -11.90600M -19.70600M -9.49400M
Net income applicable to common shares -23.18400M -15.17200M -11.89600M -19.70600M 64.01M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 79.24M 51.77M 68.72M 74.11M 84.68M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 2.73M 2.74M 1.93M 2.79M 3.58M
Total liab 52.32M 13.98M 14.71M 10.25M 13.42M
Total stockholder equity 26.70M 37.58M 53.70M 63.72M 71.26M
Deferred long term liab - - - - -
Other current liab 9.17M 8.07M 1.86M 1.66M 1.49M
Common stock 0.04M 0.04M 0.03M 0.03M 0.03M
Capital stock 0.04M 0.04M 0.03M 0.03M 0.03M
Retained earnings -54.44800M -35.73500M -12.55100M 2.62M 14.52M
Other liab - 1.59M 1.49M 0.79M 0.52M
Good will - - - - -
Other assets - 1.22M 1.11M 1.48M 0.19M
Cash 43.65M 10.19M 30.87M 41.91M 58.81M
Cash and equivalents - - - - -
Total current liabilities 12.74M 11.85M 13.21M 9.15M 12.24M
Current deferred revenue 0.49M 0.85M 8.42M 5.62M 7.91M
Net debt -5.15100M -9.39600M -30.56500M -41.23900M -57.67900M
Short term debt 0.37M 0.25M 0.29M 0.36M 0.48M
Short long term debt - - - - 0.14M
Short long term debt total 38.50M 0.80M 0.30M 0.68M 1.13M
Other stockholder equity 81.11M 73.28M 66.22M 61.07M 56.71M
Property plant equipment - 6.76M 6.58M 7.21M 6.62M
Total current assets 70.36M 42.97M 60.74M 66.09M 76.66M
Long term investments - - - - -
Net tangible assets - 37.58M 53.70M 63.72M 71.26M
Short term investments - - - - 0.00000M
Net receivables 14.05M 18.25M 21.16M 17.33M 9.22M
Long term debt 33.19M - - - -
Inventory 9.92M 11.80M 6.78M 4.05M 5.05M
Accounts payable 2.71M 2.67M 2.63M 1.51M 2.37M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - 0.21M 0.30M 0.14M -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00000M - - - -4.40300M
Additional paid in capital - - - - -
Common stock total equity - 0.04M 0.03M 0.03M 0.03M
Preferred stock total equity - - - - -
Retained earnings total equity - -35.73500M -12.55100M 2.62M 14.52M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.73M 1.22M 1.11M 0.81M 0.39M
Deferred long term asset charges - - - - -
Non current assets total 8.88M 8.80M 7.98M 8.02M 8.01M
Capital lease obligations 5.32M 0.80M 0.30M 0.68M 0.99M
Long term debt total - - - - 0.42M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -1.01000M -0.72300M -0.58100M 61.84M -61.43100M
Change to liabilities -1.14100M 4.55M -0.96500M 3.42M -16.16700M
Total cashflows from investing activities -1.01000M -0.72300M -0.58100M 60.54M 29.30M
Net borrowings -0.14800M -0.23800M -0.36900M -0.06000M -2.69400M
Total cash from financing activities 0.22M 0.02M -0.07300M 0.15M -2.49200M
Change to operating activities -1.73100M 4.75M -2.11700M 1.96M -18.19200M
Net income -23.27800M -15.20000M -11.90600M -19.70600M 64.01M
Change in cash -20.67800M -11.04500M -16.89700M 42.22M 5.80M
Begin period cash flow 30.87M 41.91M 58.81M 16.60M 10.67M
End period cash flow 10.19M 30.87M 41.91M 58.81M 16.47M
Total cash from operating activities -20.28000M -10.44900M -16.06600M -18.47500M -21.01100M
Issuance of capital stock - - - - 0.00000M
Depreciation 0.89M 0.90M 0.89M 0.75M 0.67M
Other cashflows from investing activities - - - 61.84M 91.09M
Dividends paid - - - - -
Change to inventory -5.56800M -2.85900M 0.61M -2.36700M -0.88100M
Change to account receivables 1.92M -4.90100M -0.55800M -3.97000M -0.38200M
Sale purchase of stock - 0.20M 0.15M 0.21M 0.20M
Other cashflows from financing activities 0.36M 0.26M 0.30M 0.21M 0.20M
Change to netincome 7.09M 5.58M 5.20M 3.66M -67.29000M
Capital expenditures 1.01M 0.72M 0.58M 1.30M 0.36M
Change receivables 1.92M -4.90100M -0.55800M -3.97000M -0.38200M
Cash flows other operating -0.18800M 1.48M -6.74900M -0.27400M 63.04M
Exchange rate changes - - - - -
Cash and cash equivalents changes -21.07300M -11.14800M -16.72000M 42.21M 5.80M
Change in working capital -5.21700M -1.84300M -10.25300M -3.31900M -18.39900M
Stock based compensation 6.70M 5.09M 4.21M 3.58M 1.52M
Other non cash items 0.63M 0.60M 1.00M 0.21M -68.44700M
Free cash flow -21.29000M -11.17200M -16.64700M -19.77600M -21.37400M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
APYX
Apyx Medical Inc
0.04 2.45% 1.47 - - 0.97 1.84 0.84 -2.4317
ABT
Abbott Laboratories
0.32 0.24% 135.12 37.15 23.15 4.67 4.97 4.88 19.38
SYK
Stryker Corporation
-0.46 0.12% 393.75 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC
0.38 0.43% 86.81 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp
0.40 0.37% 106.44 68.17 24.57 5.85 4.26 6.46 26.80

Reports Covered

Stock Research & News

Profile

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. The company's Helium Plasma Technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures various hand pieces for open and laparoscopic procedures; and OEM generators, as well as related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.

Apyx Medical Inc

5115 Ulmerton Road, Clearwater, FL, United States, 33760-4004

Key Executives

Name Title Year Born
Mr. Charles D. Goodwin II Pres, CEO & Director 1966
Ms. Tara H. Semb CFO, Treasurer & Sec. 1970
Mr. Moshe Citronowicz Sr. VP 1953
Mr. Todd Hornsby Exec. VP 1976
Mr. Charles D. Goodwin II President, CEO & Director 1967
Mr. Matthew C. Hill CPA CFO, Treasurer & Secretary 1969
Mr. Moshe Citronowicz Senior Vice President 1953
Mr. Todd Hornsby Executive Vice President 1977

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.